BioLargo director Bray receives 234,375-share option

The option was issued for $18,750 in fees due for Christina Elaine Bray’s board service during the most recently completed quarterly period.

Rhea-AI Filing Summary

BioLargo, Inc. director Christina Elaine Bray acquired an option to purchase 234,375 common shares on September 30, 2026, at an exercise price of $0.0800 per share, expiring September 30, 2036. The option was issued for $18,750 in fees due for board service during the most recently completed quarterly period under BioLargo’s 2024 Equity Incentive Plan. Following the grant, Bray’s reported direct options covered 1,781,075 shares.

Insider Trade Summary

Grant/Award: 234,375 shares

Grant/Award 1 txn

Insider Bray Christina Elaine

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock F1	234,375	--	--

Holdings After Transaction: Option to Purchase Common Stock — 1,781,075 contracts (Direct)

Footnotes (1)

1. F1. This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan. The number of shares in the Option is equal to the amount of fees due divided by the exercise price of the Option.

Key Figures

Option shares: 234,375 shares Exercise price: $0.0800 per share Fees due: $18,750 +2 more

5 metrics

Option shares 234,375 shares Option granted September 30, 2026

Exercise price $0.0800 per share Option to purchase common stock

Fees due $18,750 Board services for the most recently completed quarterly period

Options following transaction 1,781,075 shares Reported direct option position

Option expiration September 30, 2036 Expiration date

Key Terms

Option to Purchase Common Stock, exercise price, 2024 Equity Incentive Plan

3 terms

Option to Purchase Common Stock financial

"Option to Purchase Common Stock"

exercise price financial

"divided by the exercise price of the Option"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2024 Equity Incentive Plan financial

"pursuant to the Issuer's 2024 Equity Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What option did BLGO director Christina Elaine Bray receive?

Christina Elaine Bray received an option to purchase 234,375 BioLargo common shares on September 30, 2026, with a $0.0800 exercise price and a September 30, 2036 expiration date. It was issued for $18,750 in board-service fees under the 2024 Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 06:22 PM Accepted by SEC EDGAR 10/02/2026 - 06:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bray Christina Elaine

(Last) (First) (Middle)

14921 CHESTNUT ST.

(Street)

WESTMINSTER CALIFORNIA 92683

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOLARGO, INC. [ BLGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.08	09/30/2026		A		234,375		09/30/2026	09/30/2036	Common Stock	234,375	(1)	1,781,075	D

Explanation of Responses:

1. This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan. The number of shares in the Option is equal to the amount of fees due divided by the exercise price of the Option.

	/s/ John R. Browning, attorney-in-fact	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)